

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>ATAI Life Sciences N.V.</u>  (Last) (First) (Middle) <u>WALLSTRABE 16</u>  (Street) <u>BERLIN 2M 10179</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>IntelGenX Technologies Corp. [ IGXT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>04/19/2024</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication  <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Convertible Notes	\$0.185	04/19/2024		J <sup>(1)</sup>		\$1,000,000		04/19/2024	02/01/2026	Common Stock	5,405,405 <sup>(1)</sup>	(1)	\$10,500,000	I	By ATAI Life Sciences AG <sup>(2)</sup>

1. Name and Address of Reporting Person* <u>ATAI Life Sciences N.V.</u>  (Last) (First) (Middle) <u>WALLSTRABE 16</u>  (Street) <u>BERLIN 2M 10179</u>  (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>ATAI Life Sciences AG</u>  (Last) (First) (Middle) <u>WALLSTRABE 16</u>  (Street) <u>BERLIN 2M 10179</u>  (City) (State) (Zip)

Explanation of Responses:

- On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to \$1,000,000, which is convertible to shares of Common Stock at a price of \$0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable.
- Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.

ATAI Life Sciences N.V., By: /s/ Florian Brand, Chief Executive Officer 05/03/2024  
ATAI Life Sciences AG, By: /s/ Florian Brand, Chief Executive Officer 05/03/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.